Estramustine Phosphate 투여 중지 후 전립선특이항원의 급격한 감소와 증상의 호전을 보인 호르몬 불응성 전립선암 환자 = Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient

참고문헌 (Reference)

1 Hudes G, "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" 17 : 3160-3166, 1999

2 Gottlieb B, "The androgen receptor gene mutations database" 26 : 234-238, 1998

3 Kelly WK, "Prostate-specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome" 149 : 607-609, 1993

4 Miyamoto H, "Molecular basis for the antiandrogen withdrawal syndrome" 91 : 3-12, 2004

5 Nishiyama T, "Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer" 5 : 44-47, 1998

6 Shibata Y, "Estramustine phosphate withdrawal syndrome with dramatic pain relief" 162 : 805-, 1999

7 Kobayashi M, "Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer" 13 : 1019-1021, 2006

8 Suzuki H, "Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome" 29 : 153-158, 1996